Ignite Creation Date:
2025-12-24 @ 3:53 PM
Ignite Modification Date:
2026-04-02 @ 4:20 AM
Study NCT ID:
NCT00105092
Status:
COMPLETED
Last Update Posted:
2007-05-01
First Post:
2005-03-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
Sponsor:
Eli Lilly and Company
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
8670
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None